BIOGEN INC. - COMMON STOCK

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

30 июн 2025 04:30:12 Источник Nasdaq GlobeNewswire

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

27 июн 2025 07:00:23 Источник Nasdaq GlobeNewswire

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

25 июн 2025 04:30:37 Источник Nasdaq GlobeNewswire

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

18 июн 2025 04:30:27 Источник Nasdaq GlobeNewswire

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

11 июн 2025 22:00:39 Источник Nasdaq GlobeNewswire

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

27 май 2025 04:30:00 Источник Nasdaq GlobeNewswire

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

15 апр 2025 16:00:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

09 апр 2025 06:45:15 Источник NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

08 апр 2025 10:06:04 Источник NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

07 апр 2025 06:45:03 Источник NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

04 апр 2025 06:47:36 Источник NetDania Notify

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

02 апр 2025 04:30:00 Источник Nasdaq GlobeNewswire

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

24 мар 2025 04:30:00 Источник Nasdaq GlobeNewswire

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

11 мар 2025 04:30:00 Источник Nasdaq GlobeNewswire

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

18 фев 2025 05:00:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

12 фев 2025 06:45:10 Источник NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

11 фев 2025 08:11:08 Источник NetDania Notify

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

31 янв 2025 03:30:52 Источник Nasdaq GlobeNewswire

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

26 янв 2025 15:33:52 Источник Nasdaq GlobeNewswire

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

23 янв 2025 04:30:54 Источник Nasdaq GlobeNewswire